D-甘露糖 | 7296-15-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: D-甘露糖
• 中文别名: α-D-吡喃甘露糖
• 英文名称: alpha-D-mannopyranoside
• 英文别名: D-(+)-mannose；alpha-D-Mannopyranose；α-D-mannopyranose；α-D-mannose；mannose；(2S,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
• CAS: 7296-15-3
• 化学式: C₆H₁₂O₆
• 分子量: 180.158
• InChiKey: WQZGKKKJIJFFOK-PQMKYFCFSA-N

物化性质

• 熔点：
  133 °C
• 沸点：
  410.8±45.0 °C(Predicted)
• 密度：
  1.732±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 溶解度：
  713.0 mg/mL at 17 °C
• 蒸汽压力：
  8.02e-14 mmHg

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  D-甘露糖 在 吡啶 、 咪唑 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 selenium(IV) oxide 、 羟胺 、 sodium hydride 、 对甲苯磺酸 、 三乙胺 、 乙酰氯 、 pyridinium chlorochromate 作用下， 以 甲醇 、 乙醚 、 溶剂黄146 为溶剂， 生成 N-{(2R,4R,5R)-4-[(1S,2R)-1,2-Bis-benzyloxy-3-(tert-butyl-dimethyl-silanyloxy)-propyl]-2-phenyl-[1,3]dioxan-5-yl}-acetamide
  参考文献：
  名称：

  Synthesis of a novel dioxan sialic acid analog

  摘要：

  A preparative scale synthesis of a dioxan sialic acid analog was achieved from D-mannose. The conformation and the acidic character of this dioxan derivative, closely related to sialic acid. provides a scaffold for drug design. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.03.135
• 作为产物：
  描述：

  Α-D-氟代吡喃甘露糖 以 acetate buffer 、 溶剂黄146 为溶剂， 生成 D-甘露糖
  参考文献：
  名称：

  Simultaneous detection of different glycosidase activities by 19F NMR spectroscopy

  摘要：

  A fast method for the simultaneous detection of different glycosidolytic activities in commercially available enzyme preparations and crude culture filtrates was found in using, as substrate, a mixture of different glycosyl fluorides and F-19 NMR spectroscopy as a screening technique. Accompanying studies regarding the hydrolytic stability of these fluorides in various buffer systems, as well as conditions of their long-term storage, were carried out. A simple procedure for the preparation of beta-D-mannopyranosyl fluoride in gram quantities is given. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0008-6215(00)00060-4

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• KINASE MODULATORS FOR THE TREATMENT OF CANCER
  申请人：Synovo GmbH

  公开号：US20170313661A1

  公开（公告）日：2017-11-02

  A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.

  一种治疗癌症的方法，其中抑制免疫细胞表达、产生或释放IL-10的化合物与在与TNFa联合给予或存在的情况下刺激IL-12产生的化合物结合。所述方法在提供标准疗法的基础上有效，特别是包括使用细胞毒性药物的化疗和其他形式的免疫疗法，包括治疗性疫苗。
• [EN] INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES<br/>[FR] INTERMÉDIAIRES UTILES POUR LA SYNTHÈSE DE PYRROLOBENZODIAZÉPINES
  申请人：SPIROGEN LTD

  公开号：WO2011128650A1

  公开（公告）日：2011-10-20

  A compound of formula (I): which is substantially free of any of the corresponding compound of formula (IB): methods of making such compounds, and the further transformation of such compounds.

  具有式（I）的化合物：基本上不含有式（IB）对应的任何化合物；制备这种化合物的方法，以及这种化合物的进一步转化。
• [EN] PYRROLOBENZODIAZEPINE CONJUGATES<br/>[FR] CONJUGUÉS DE PYRROLOBENZODIAZÉPINE
  申请人：MEDIMMUNE LTD

  公开号：WO2018192944A1

  公开（公告）日：2018-10-25

  A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; R" is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y' are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.

  化合物I的结构式及其盐和溶剂化合物，其中：R6和R9分别选自H、R、OH、OR、SH、SR、NH2、NHR、NRR'、硝基、Me3Sn和卤素；其中R和R'分别选自可选择取代的C1-12烷基、C3-20杂环烷基和C5-20芳基；R7选自H、R、OH、OR、SH、SR、NH2、NHR、NRR'、硝基、Me3Sn和卤素；R"是C3-12烷基基团，该链可被一个或多个杂原子（例如O、S、NRN2（其中RN2为H或C1-4烷基））和/或芳香环（例如苯或吡啶）中断；Y和Y'选自O、S或NH；R6、R7、R9分别选自与R6、R7和R9相同的基团；R11b选自OH、ORA，其中RA为C1-4烷基；RL是用于连接到细胞结合剂的连接剂。
• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。